Results 21 to 30 of about 98,417 (285)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

Journal of Hematology & Oncology, 2011
Background The objectives of the present study are to investigate the efficacy and safety profile of gemcitabine-based combinations in the treatment of locally advanced and metastatic pancreatic adenocarcinoma (LA/MPC).
Ma Yue, Xu Ying-Chun, Tang Lei, Wang Hong-Xia, Zhao Gang, Hu Jing, Zhang Feng-Chun   +6 more
doaj   +1 more source

Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group [PDF]

, 2005
Purpose: This phase III randomized trial compared two chemotherapy regimens, gemcitabine plus carboplatin and mitomycin, ifosfamide, and cisplatin, in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC).
Harper, P.G., Johnson, P.W.M., Harper, P. G., Qian, W., Rudd, R. M., Spiro, S.G., Gregory, W. M., Hatton, M., Eisen, T. G., James, L.E., Rankin, E. M., Johnson, P. W. M., Rankin, E.M., Spiro, S. G., Rudd, R.M., Lee, S. M., Littler, J. A. H., Lee, S.M., Littler, J.A.H., Eisen, T.G., Martin, W.M.C., Gregory, W.M., James, L. E., Gower, N. H., Martin, W. M. C., Gower, N.H.   +25 more
core   +1 more source

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy? [PDF]

, 2007
Background: The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information ...
Holdenrieder, Stefan, Weckbach, Sabine, Schulz, Christoph, Boeck, Stefan, Heinemann, Volker, Stieber, Petra   +5 more
core   +1 more source

Challenges of drug resistance in the management of pancreatic cancer [PDF]

, 2010
The current treatment of choice for metastatic pancreatic cancer involves single agent gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine kinase inhibitor).
Naomi Walsh, Martin Clynes, Rizwan Sheikh, Sheikh, Rizwan, O'Connor, Robert A., Robert O’Connor, Ray McDermott, O'Connor, Robert, Clynes, Martin, Walsh, Naomi, McDermott, Ray   +10 more
core   +1 more source

Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma

Cancer Biology & Medicine, 2023
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery.
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao   +19 more
doaj   +1 more source

Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. [PDF]

, 2011
Irinotecan-containing regimens are known to be active and tolerable in patients with non-small cell lung cancer (NSCLC). A randomized phase II trial was conducted to evaluate the efficacy of irinotecan plus paclitaxel or gemcitabine for previously ...
Akitoshi Kinoshita, Kasai, Takashi, Nagashima, Seiji, Soejima, Yoshifumi, Yoshifumi Soejima, Tsukamoto, Kazuhiro, Fukuda, Minoru, Katsumi Nakatomi, Takatani, Hiroshi, Shigeru Kohno, Minoru Fukuda, Seiji Nagashima, Fukuda, Masaaki, Kazuhiro Tsukamoto, Yoichi Nakamura, Mikio Oka, Masuda, Noriyuki, Nakamura, Yoichi, Hiroshi Soda, Hiroshi Takatani, Oka, Mikio, Nakatomi, Katsumi, Masaaki Fukuda, Noriyuki Masuda, Kohno, Shigeru, Kinoshita, Akitoshi, Soda, Hiroshi, Takashi Kasai   +27 more
core   +1 more source

Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway

Redox Biology, 2019
Chemoresistance is a major therapeutic obstacle in the treatment of human pancreatic ductal adenocarcinoma (PDAC). As an oxidative stress responsive transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2) regulates the expression of ...
Yunjiang Zhou, Yang Zhou, Mengdi Yang, Keke Wang, Yisi Liu, Mingda Zhang, Yunjia Yang, Chenyu Jin, Rui Wang, Rong Hu   +9 more
doaj   +1 more source

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine

Scientific Reports, 2022
Chemotherapy is a standard therapy for muscle-invasive bladder cancer (MIBC). However, genomic alterations associated with chemotherapy sensitivity in MIBC have not been fully explored.
Shigehiro Tsukahara, Masaki Shiota, Dai Takamatsu, Shohei Nagakawa, Takashi Matsumoto, Ryo Kiyokoba, Mikako Yagi, Daiki Setoyama, Nozomi Noda, Shinya Matsumoto, Tetsutaro Hayashi, Alberto Contreras-Sanz, Peter C. Black, Junichi Inokuchi, Kenichi Kohashi, Yoshinao Oda, Takeshi Uchiumi, Masatoshi Eto, Dongchon Kang   +18 more
doaj   +1 more source

Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. [PDF]

, 2013
Copyright: 2013 Hermann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source ...
Tunici, P, Stephan A. Hahn (423002), Hidalgo Manuel, Annette Bakker (109705), Trabulo Sara M., Hermann, PC, Hahn, SA, Patrizia Tunici (109691), Patrick C. Hermann, Hahn Stephan A., Vandana, M, Sanjeeb K. Sahoo (176483), Sahoo Sanjeeb K., Sainz, B, Sainz Bruno, Anamaria Balic (423000), Garcia Elena, Tunici Patrizia, Manuel Hidalgo, Balic, A, Balic Anamaria, Stephan A. Hahn, Vandana Mallaredy, Elena Garcia (423001), Stephan A Hahn, Christopher Heeschen (373899), Sahoo, SK, Patrizia Tunici, Bakker Annette, Mallaredy Vandana, Heeschen Christopher, Patrick C Hermann, Bruno Sainz, Sara M Trabulo, Sara M. Trabulo, Christopher Heeschen, Patrick C. Hermann (422997), Garcia, E, Mallaredy Vandana (423003), Elena Garcia, Sanjeeb K Sahoo, Heeschen, C, Manuel Hidalgo (7235), Bakker, A, Bruno Sainz Jr (422999), Sanjeeb K. Sahoo, Hermann Patrick C., Sara M. Trabulo (422998), Trabulo, SM, Anamaria Balic, Hidalgo, M, Annette Bakker   +51 more
core   +1 more source

Gut microbiota–derived short‐chain fatty acids regulate group 3 innate lymphoid cells in HCC

Hepatology, EarlyView., 2022
Abstract Background and Aims Type 3 innate lymphoid cells (ILC3s) are essential for host defense against infection and tissue homeostasis. However, their role in the development of HCC has not been adequately confirmed. In this study, we investigated the immunomodulatory role of short‐chain fatty acids (SCFAs) derived from intestinal microbiota in ILC3
Chupeng Hu, Bingqing Xu, Xiaodong Wang, Wen‐Hua Wan, Jinying Lu, Deyuan Kong, Yu Jin, Wenhua You, Hua Sun, Xiaoxin Mu, Dongju Feng, Yun Chen   +11 more
wiley   +1 more source